Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MST vs NST in Intermediate-risk AML
NCT02461121Phase 3Completed
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- May 2004
- Primary completion
- May 2013
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) (2 arms), sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Overall Survival at 10 years. Started May 2004; status: completed.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02461121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461121.